InvestorsHub Logo
Followers 4
Posts 1139
Boards Moderated 0
Alias Born 04/27/2006

Re: None

Wednesday, 09/30/2015 1:35:58 PM

Wednesday, September 30, 2015 1:35:58 PM

Post# of 8438
Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab

Conditions:
NSCLC; Gastric Cancer

Intervention:
Drug: PEGPEM

Phase:
Phase 1

Sponsor:
Halozyme Therapeutics

Study Start:
October 2015

Primary Completion:
December 2017

First Received:
August 31, 2015

Last Updated:
September 29, 2015

Never argue with a fool, for after awhile, it becomes difficult to determine which is the fool.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News